Regulatory Intelligence
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
|
About the Regulatory Intelligence category
|
|
0 | 254 | August 3, 2023 |
|
FDA Requirement to inform about nitrosamine risk in ongoing/new clinical trials
|
|
2 | 164 | December 13, 2024 |
|
Variation for new spec due to updated EMA Guideline
|
|
7 | 589 | July 16, 2024 |
|
Regulatory Differences between EMA and FDA on Nitrosamines
|
|
1 | 464 | June 25, 2024 |
|
Entidades regulatorias y su postura en el análisis de nitrosaminas en estudios de estabilidad de preparados farmacéuticos
|
|
0 | 245 | February 28, 2024 |
|
Adoption of CPCA beyond FDA/ EMA
|
|
9 | 1004 | January 31, 2024 |
|
Would we expect new regulations evolution for "PFAS" similar to what the industry had for Nitrosamines since 2018?
|
|
1 | 416 | December 19, 2023 |
|
Risk for dossier submission link to secondary amine present on API related impurity
|
|
0 | 364 | December 8, 2023 |